DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC

PHASE4TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 9, 2013

Primary Completion Date

October 12, 2015

Study Completion Date

October 12, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Gadoterate meglumine

Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.

Trial Locations (1)

135-920

Guerbet Korea, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Guerbet

INDUSTRY

NCT01806740 - DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC | Biotech Hunter | Biotech Hunter